Summary by Moomoo AI
BeiGene announced Q3 2024 financial results, reporting $1 billion in total revenue, a 28% increase year-over-year. Product revenue grew 67% to $993 million, driven by BRUKINSA sales growth of 87% in the U.S. and 217% in Europe. The company reduced its GAAP operating loss by 10% and achieved a second consecutive quarter of positive non-GAAP operating income at $66 million.BRUKINSA continued to strengthen its leadership in chronic lymphocytic leukemia, becoming the leader in new patient starts for both frontline and relapsed/refractory settings in the U.S. BeiGene expanded its oncology pipeline, with four new molecular entities entering the clinic this quarter, bringing the year-to-date total to eight. The company reaffirmed its goal to have 10+ new molecular entities enter the clinic by year...Show More